A photo of Michael Pauciulo.

Michael W. Pauciulo, MBA

  • Director, Discover Together Biobank
  • Assistant Professor, UC Department of Pediatrics



As the director of the Discover Together Biobank at Cincinnati Children’s Hospital Medical Center, I work to provide an ongoing and growing institutional resource of biospecimens, clinical data and genomic data to help further research and increase grant competitiveness for all our researchers. Our end goal is to improve outcomes for our patients and our community.

My early career interest and research in pulmonary arterial hypertension (PAH) led me to working on the National Institutes of Health (NIH)-funded PAH Biobank. Built from scratch, the biobank is the largest consecutively enrolled collection of PAH patient participants in the world. The PAH Biobank is now a widely used resource that has resulted in numerous grants and publications.

My experience building the PAH Biobank led me to my position as director of the Discover Together Biobank. Discover Together actively partners with researchers at Cincinnati Children’s to provide biobanking infrastructure, institutional biospecimens and associated clinical/genetic data. Fostering internal and external collaboration whenever possible, Discover Together accelerates research and builds upon our existing resource for investigators at Cincinnati Children’s. My current research areas of interest include:

  • Biobanking
  • Biorepository projects
  • Community cohorts
  • Pulmonary arterial hypertension


Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity. Alotaibi, M; Shao, J; Pauciulo, MW; Nichols, WC; Hemnes, AR; Malhotra, A; Kim, NH; Yuan, JX-J; Fernandes, T; Kerr, KM; et al. Chest. 2022.

Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. Harbaum, L; Rhodes, CJ; Wharton, J; Lawrie, A; Karnes, JH; Desai, AA; Nichols, WC; Humbert, M; Montani, D; Girerd, B; et al. American Journal of Respiratory and Critical Care Medicine. 2022; 205:1449-1460.

COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study. Simpson, CE; Griffiths, M; Yang, J; Nies, MK; Vaidya, D; Brandal, S; Martin, LJ; Pauciulo, MW; Lutz, KA; Coleman, AW; et al. ERJ Open Research. 2022; 8.

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. Toshner, M; Church, C; Harbaum, L; Rhodes, C; Villar Moreschi, SS; Liley, J; Jones, R; Arora, A; Batai, K; Desai, AA; et al. European Respiratory Journal. 2022; 59.

Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. Griffiths, M; Yang, J; Vaidya, D; Nies, M; Brandal, S; Ivy, DD; Hickey, F; Wolter-Warmerdam, K; Austin, ED; Mullen, M; et al. Journal of Pediatrics. 2022; 241:68-76.e3.

Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival. Yang, J; Ambade, AS; Nies, M; Griffiths, M; Damico, R; Vaidya, D; Brandal, S; Pauciulo, MW; Lutz, KA; Coleman, AW; et al. Pulmonary Circulation. 2022; 12.

Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Zhu, N; Swietlik, EM; Welch, CL; Pauciulo, MW; Hagen, JJ; Zhou, X; Guo, Y; Karten, J; Pandya, D; Tilly, T; et al. Genome Medicine. 2021; 13.

Validation of low-coverage whole-genome sequencing for mitochondrial DNA variants suggests mitochondrial DNA as a genetic cause of preterm birth. Yang, Z; Slone, J; Wang, X; Zhan, J; Huang, Y; Namjou, B; Kaufman, KM; Pauciulo, M; Harley, JB; Muglia, LJ; et al. Human Mutation. 2021; 42:1602-1614.

Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. Daly, CM; Griffiths, M; Simpson, CE; Yang, J; Damico, RL; Vaidya, RD; Williams, M; Brandal, S; Jone, PN; Polsen, C; et al. Journal of the American Heart Association. 2021; 10.

The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. Simpson, CE; Griffiths, M; Yang, J; Nies, MK; Vaidya, RD; Brandal, S; Martin, LJ; Pauciulo, MW; Lutz, KA; Coleman, AW; et al. ERJ Open Research. 2021; 7.